Last 7 days
-11.7%
Last 30 days
-7.0%
Last 90 days
9.3%
Trailing 12 Months
4.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 440.9B | 324.2B | -6.04% | -5.61% | 21.91 | 1.36 | 12.71% | 16.40% |
CVS | 98.6B | 322.5B | -16.10% | -28.31% | 23.76 | 0.31 | 10.39% | -47.55% |
CERN | 27.9B | - | 0.98% | 20.75% | 47.36 | 4.81 | - | - |
VEEV | 27.3B | 2.1B | -0.47% | -1.83% | 68.93 | 13.15 | 17.88% | -8.53% |
MID-CAP | ||||||||
CHNG | 9.0B | 3.5B | 11.88% | 31.28% | -116.8 | 2.57 | 7.15% | -34.72% |
RCM | 6.5B | - | -7.53% | -10.06% | 64.74 | 4.3 | - | - |
TDOC | 4.1B | 2.4B | -16.92% | -54.15% | -0.3 | 1.71 | 18.41% | -3085.58% |
PINC | 3.8B | 1.4B | -2.87% | -11.96% | 21.41 | 2.78 | -19.68% | -41.10% |
EVH | 3.0B | 1.4B | -7.00% | 4.56% | -157.77 | 2.24 | 48.91% | 49.03% |
SMALL-CAP | ||||||||
PHR | 1.8B | 262.3M | -10.85% | 40.30% | -9.92 | 6.98 | 33.16% | -131.28% |
NXGN | 1.1B | 625.9M | -11.35% | -14.10% | 49.5 | 1.81 | 6.21% | 3223.77% |
SLP | 864.4M | 53.5M | 4.26% | 2.91% | 80.77 | 16.17 | 10.94% | 3.61% |
HCAT | 657.1M | 276.2M | -14.12% | -43.94% | -4.78 | 2.38 | 14.18% | 10.32% |
OPRX | 234.3M | 63.1M | -26.73% | -64.73% | -22.34 | 3.71 | 9.93% | -1043.45% |
TRHC | 155.2M | 357.1M | -7.94% | 20.85% | -1.11 | 0.43 | 33.22% | -57.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 11.0% | 1,352 | 1,218 | 1,088 | 990 | 908 |
Operating Expenses | 7.2% | 1,019 | 950 | - | - | - |
S&GA Expenses | 6.3% | 269 | 253 | 236 | 220 | 219 |
R&D Expenses | - | 16.00 | - | - | - | - |
EBITDA | -28.2% | 21.00 | 29.00 | 59.00 | 58.00 | - |
EBITDA Margin | -35.3% | 0.02* | 0.02* | 0.05* | 0.06* | - |
Earnings Before Taxes | -26.0% | -62.08 | -49.25 | -18.66 | -23.37 | -29.80 |
EBT Margin | -13.5% | -0.05* | -0.04* | -0.02* | -0.02* | - |
Interest Expenses | -0.1% | 16.00 | 16.00 | 17.00 | 21.00 | 25.00 |
Net Income | -42.4% | -19.16 | -13.46 | -28.62 | -33.14 | -37.60 |
Net Income Margin | -28.2% | -0.01* | -0.01* | -0.03* | -0.03* | - |
Free Cahsflow | -159.5% | -11.55 | 19.00 | 67.00 | 29.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 3.3% | 1,817 | 1,759 | 1,304 | 1,339 | 1,419 |
Current Assets | 21.4% | 478 | 394 | 423 | 463 | 524 |
Cash Equivalents | 20.1% | 188 | 157 | 193 | 210 | 266 |
Net PPE | -7.2% | 88.00 | 95.00 | 93.00 | 83.00 | 81.00 |
Goodwill | 0.0% | 723 | 723 | 426 | 426 | 426 |
Liabilities | 6.1% | 958 | 903 | 691 | 728 | 726 |
Current Liabilities | 13.5% | 433 | 382 | 343 | 382 | 445 |
LT Debt, Current | - | - | - | - | - | - |
LT Debt, Non Current | 0.1% | 413 | 412 | 283 | 283 | 216 |
Shareholder's Equity | 0.4% | 859 | 856 | 613 | 611 | 694 |
Retained Earnings | -1.9% | -606 | -594 | -596 | -592 | -626 |
Additional Paid-In Capital | 1.0% | 1,487 | 1,472 | 1,231 | 1,224 | 1,341 |
Shares Outstanding | 5.8% | 95.00 | 90.00 | 90.00 | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -159.5% | -11.55 | 19.00 | 67.00 | 29.00 | 39.00 |
Share Based Compensation | 39.8% | 34.00 | 24.00 | 22.00 | 18.00 | 17.00 |
Cashflow From Investing | 16.2% | -259 | -309 | -55.84 | -44.97 | -15.79 |
Cashflow From Financing | -35.3% | 132 | 203 | 31.00 | -25.34 | -29.55 |
95.8%
83.5%
47.7%
Y-axis is the maximum loss one would have experienced if Evolent Health was unfortunately bought at previous high price.
17.3%
15.7%
76.8%
FIve years rolling returns for Evolent Health.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 23.55 | -1,270,850 | 35,661,200 | 0.04% |
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | -1,000 | 3,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | 110 | 6,016,230 | 15,390,200 | 0.02% |
2023-02-24 | NATIXIS | new | - | 634,917 | 634,917 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -23.91 | -21,241,000 | 31,080,000 | 0.04% |
2023-02-17 | Ascent Group, LLC | reduced | -1.31 | -62,396 | 422,604 | 0.05% |
2023-02-17 | TRUIST FINANCIAL CORP | reduced | -1.53 | -922,698 | 3,081,300 | -% |
2023-02-16 | IMA Wealth, Inc. | reduced | -5.91 | -833,152 | 2,313,850 | 0.61% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | reduced | -5.59 | -61,485 | 388,515 | 0.02% |
2023-02-15 | GABELLI & Co INVESTMENT ADVISERS, INC. | unchanged | - | -62,360 | 224,640 | 0.05% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 08, 2023 | upmc | 1.97% | 2,190,702 | SC 13G/A | |
Feb 14, 2023 | granahan investment management, llc | 3.12% | 3,155,211 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.68% | 9,790,816 | SC 13G/A | |
Feb 03, 2023 | upmc | 5.84% | 5,907,841 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.6% | 7,701,919 | SC 13G/A | |
Jan 27, 2023 | magellan health inc | 8.4% | 8,474,576 | SC 13G | |
Jan 20, 2023 | jpmorgan chase & co | 5.3% | 5,368,825 | SC 13G/A | |
Aug 25, 2022 | engaged capital llc | 2.8% | 2,585,187 | SC 13D/A | |
Jul 11, 2022 | engaged capital llc | 3.2% | 2,936,627 | SC 13D/A | |
May 09, 2022 | engaged capital llc | 4.4% | 3,989,962 | SC 13D/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 19.97 -37.06% | 29.82 -6.02% | 50.36 58.71% | 82.44 159.82% | 138.30 335.87% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 08, 2023 | SC 13G/A | Major Ownership Report | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-07 | Blackley Seth | sold | -3,290,800 | 34.62 | -95,055 | chief executive officer |
2023-03-07 | WILLIAMS FRANK J | sold | -4,026,690 | 34.62 | -116,311 | - |
2023-03-06 | WILLIAMS FRANK J | sold | -3,109,740 | 34.4166 | -90,356 | - |
2023-03-06 | Blackley Seth | sold | -2,544,350 | 34.4166 | -73,928 | chief executive officer |
2023-03-03 | WILLIAMS FRANK J | acquired | - | - | 400,000 | - |
2023-03-03 | Blackley Seth | acquired | - | - | 360,000 | chief executive officer |
2023-03-02 | Weinberg Jonathan | sold (taxes) | -117,050 | 35.15 | -3,330 | general counsel |
2023-03-02 | Tutewohl Steve | sold (taxes) | -112,480 | 35.15 | -3,200 | chief operating officer |
2023-03-02 | Johnson John Paul | sold (taxes) | -317,053 | 35.15 | -9,020 | chief financial officer |
2023-03-02 | McCarthy Daniel Joseph | sold (taxes) | -164,748 | 35.15 | -4,687 | president |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands | 3 Months Ended | 12 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |||||
Income Statement [Abstract] | ||||||||
Revenue | [1] | $ 1,352,013,000 | $ 907,957,000 | $ 924,639,000 | ||||
Expenses | ||||||||
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) | [1] | 1,035,429,000 | 657,551,000 | 696,581,000 | ||||
Selling, general and administrative expenses | [1] | 269,269,000 | 219,499,000 | 210,412,000 | ||||
Depreciation and amortization expenses | 67,195,000 | 60,037,000 | 60,835,000 | |||||
Loss on disposal of assets and consolidation | 0 | 0 | 698,000 | |||||
Goodwill impairment | 0 | 0 | 215,100,000 | |||||
Change in fair value of contingent consideration | (23,522,000) | 13,281,000 | 3,860,000 | |||||
Total operating expenses | $ 384,310,000 | 1,348,371,000 | 950,368,000 | 1,187,486,000 | ||||
Operating income (loss) | 3,642,000 | (42,411,000) | (262,847,000) | |||||
Interest income | 1,369,000 | 407,000 | 2,633,000 | |||||
Interest expense | (15,572,000) | (25,425,000) | (28,325,000) | |||||
Impairment of equity method investments | 0 | 0 | 47,133,000 | |||||
Gain from equity method investees | 4,569,000 | 13,179,000 | 10,039,000 | |||||
Gain on transfer of membership | 0 | 45,938,000 | 0 | |||||
Loss on extinguishment/repayment of debt | (10,192,000) | (21,343,000) | (4,789,000) | |||||
Change in tax receivable agreement liability | (45,950,000) | 0 | 0 | |||||
Other income (expense), net | 57,000 | (146,000) | (118,000) | |||||
Loss from continuing operations before income taxes | (62,077,000) | (29,801,000) | (330,540,000) | |||||
Provision for (benefit from) income taxes | (43,376,000) | 483,000 | (2,368,000) | |||||
Loss from continuing operations | (18,701,000) | (30,284,000) | (328,172,000) | |||||
Loss from discontinued operations, net of tax | [2] | (463,000) | (7,317,000) | (6,074,000) | ||||
Net loss attributable to common shareholders of Evolent Health, Inc - Basic | (11,349,000) | (19,164,000) | (37,601,000) | (334,246,000) | ||||
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted | $ (11,349,000) | $ (19,164,000) | $ (37,601,000) | $ (334,246,000) | ||||
Basic and diluted: | ||||||||
Continuing operations (in dollars per share) | $ (0.11) | $ (0.20) | $ (0.35) | $ (3.86) | ||||
Continuing operations (in dollars per share) | (0.11) | (0.20) | (0.35) | (3.86) | ||||
Discontinued operations (in dollars per share) | 0 | 0 | (0.09) | (0.08) | ||||
Discontinued operations (in dollars per share) | $ 0 | 0 | (0.09) | (0.08) | ||||
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) | (0.20) | (0.44) | (3.94) | |||||
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) | $ (0.20) | $ (0.44) | $ (3.94) | |||||
Weighted-average common shares outstanding | ||||||||
Basic (in shares) | 93,699 | 86,067 | 84,928 | |||||
Diluted (in shares) | 93,699 | 86,067 | 84,928 | |||||
Comprehensive loss | ||||||||
Net loss | $ (19,164,000) | $ (37,601,000) | $ (334,246,000) | |||||
Other comprehensive loss, net of taxes, related to: | ||||||||
Foreign currency translation adjustment | (816,000) | (84,000) | (44,000) | |||||
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | $ (19,980,000) | $ (37,685,000) | $ (334,290,000) | |||||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 | ||
---|---|---|---|---|
Current assets: | ||||
Cash and cash equivalents | $ 188,200 | $ 266,280 | ||
Restricted cash and restricted investments | 14,492 | 75,685 | ||
Accounts receivable, net | [1] | 254,684 | 130,604 | |
Prepaid expenses and other current assets | [1] | 20,678 | 51,391 | |
Total current assets | 478,054 | 523,960 | ||
Restricted cash and restricted investments | 12,466 | 12,977 | ||
Investments in equity method investees | 4,475 | 5,458 | ||
Property and equipment, net | 87,874 | 81,365 | ||
Right-of-use assets - operating | 49,027 | 50,203 | ||
Prepaid expenses and other noncurrent assets | [1] | 2,378 | 6,790 | |
Contract cost assets | 17,461 | 32,624 | ||
Intangible assets, net | 442,784 | 279,784 | ||
Goodwill | 722,774 | 426,297 | ||
Total assets | 1,817,293 | 1,419,458 | ||
Current liabilities: | ||||
Accounts payable | [1] | 57,174 | 96,084 | |
Accrued liabilities | [1] | 111,198 | 107,241 | |
Operating lease liability - current | 7,122 | 7,069 | ||
Accrued compensation and employee benefits | 52,460 | 51,861 | ||
Deferred revenue | 5,758 | 11,944 | ||
Reserve for claims and performance-based arrangements | [1] | 199,730 | 171,294 | |
Total current liabilities | 433,442 | 445,493 | ||
Long-term debt, net | 412,986 | 215,676 | ||
Other long-term liabilities | 4,744 | 5,531 | ||
Tax receivable agreement liability | 45,950 | 0 | ||
Operating lease liabilities - noncurrent | 56,010 | 57,722 | ||
Deferred tax liabilities, net | 4,744 | 1,403 | ||
Total liabilities | 957,876 | 725,825 | ||
Commitments and Contingencies (See Note $11) | ||||
Shareholders' Equity | ||||
Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,500,558 and 90,758,318 shares issued, respectively | 1,015 | 908 | ||
Additional paid-in-capital | 1,486,857 | 1,340,989 | ||
Accumulated other comprehensive loss | (1,178) | (362) | ||
Retained earnings (accumulated deficit) | (606,154) | (626,779) | ||
Treasury stock, at cost; 1,537,582 shares issued, respectively | (21,123) | (21,123) | ||
Total shareholders' equity | 859,417 | 693,633 | ||
Total liabilities and shareholders' equity | $ 1,817,293 | $ 1,419,458 | ||
|